Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates

Inhibrx's INBRX-106 plus Keytruda achieved a 48.3% confirmed objective response rate versus 26.5% for Keytruda alone in first-line PD-L1-positive head and neck cancer, while median progression-free survival improved to 9.6 months from 4.9 months. In HPV-positive patients, the combination delivered an 80% response rate versus 33.3% and a 30% complete-response rate, with 90% progression-free at six months. Inhibrx plans to expand the Phase 2 HPV-positive cohort by roughly 50 patients and seek FDA alignment on an accelerated pathway and confirmatory Phase 3 trial; despite the favorable data, INBX shares fell 12.49% to $106.03.

Analysis

The selloff likely reflects a valuation-and-evidence gap rather than a negative efficacy read: INBX now needs to convert a small, potentially heterogeneous dataset into a credible registrational path. The key diligence issue is durability—particularly median duration of response, mature progression-free survival, discontinuation rates, and any treatment-related deaths—not the headline response separation. Without those data, the market will discount the apparent benefit as vulnerable to small-cohort variability and an unusually weak control-arm outcome.

The HPV-positive signal is commercially important but also the most statistically fragile: enrichment could support a narrower expedited pathway, while limiting the addressable population and ultimately pricing power. FDA alignment is the next 1-3 month catalyst, but agreement to discuss acceleration is materially different from agreement on an approval-enabling endpoint; a requirement for randomized confirmatory evidence would push meaningful revenue beyond 2029 and compress the current pipeline premium.

MRK has negligible near-term earnings sensitivity, but an externally validated combination benefit would reinforce Keytruda's role as the immunotherapy backbone rather than create a competitive threat. The more relevant second-order implication is strategic: positive durability data could make INBX an acquisition or partnership candidate for oncology franchises needing post-Keytruda combination assets, though that optionality should not be underwritten before FDA feedback and fuller safety disclosure.

Contrarian view: the initial decline may be overdone if the detailed dataset shows durable complete responses and clean toxicity, because the current reaction appears to penalize trial-design uncertainty more than the magnitude of efficacy. Conversely, a rebound based solely on response-rate headlines is vulnerable; absence of mature duration-of-response or a restrictive FDA position would likely produce another 20-30% drawdown in a clinical-stage name.

Key Decisions for Investors

• Do not chase INBX on the initial efficacy headline; place it on an FDA-meeting and detailed-data watchlist for the next 1-3 months. Upgrade only if duration of response, grade 3+ adverse-event rates, and discontinuation rates demonstrate that the efficacy gain is not purchased with materially worse tolerability.
• For high-risk biotech sleeves, consider a small INBX starter position only after the stock stabilizes above the post-data low and management discloses the accelerated-approval framework. Size for binary regulatory risk; target a 2:1 upside/downside profile, with thesis invalidated by FDA requiring a fully powered Phase 3 before filing or by a material safety imbalance.
• Avoid using MRK as a direct expression of the result. Any incremental Keytruda utilization from this regimen would be immaterial versus MRK's broader oncology revenue base; MRK becomes relevant only if combination data establish a repeatable post-2028 lifecycle-management pathway.
• Use XBI as the sector hedge rather than shorting MRK against INBX: long INBX / short XBI can isolate program-specific upside after FDA clarity, but only if INBX liquidity and borrow-adjusted execution support the trade. Exit if the HPV cohort expansion fails to reproduce durable responses or if the confirmatory-study design materially delays registration.